Bayesian Capital Management, LP Apellis Pharmaceuticals, Inc. Transaction History

Bayesian Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 15, 2025	BUY	$21.87 - $34.63 $828,873 - $1.31 Million	37,900 New	37,900 $828,000
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $899,808 - $1.28 Million	31,200 New	31,200 $899,000
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $641,593 - $1.12 Million	17,275 New	17,275 $1.03 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $674,784 - $821,128	-8,800 Reduced 49.1%	9,124 $831,000
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $835,079 - $1.2 Million	17,924 New	17,924 $1.18 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $84,168 - $142,104	-2,400 Reduced 17.14%	11,600 $525,000
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $496,440 - $757,680	14,000 New	14,000 $711,000

294

132M

2.97M

623K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.77B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.